Obstetrics and Gynecology · 1999 · 137 citations · 11 references
MedicineGynecologyObstetricsCervical DiseaseGynecologic OncologyReproductive MedicineCervical CancerCervical CytologyCervical HistopathologyCervical Intraepithelial NeoplasiaCervical LesionsCervical PathologyCervical Intraepithelial Neoplasia DiagnosisClinic-based Postpartum Follow-upColposcopic AppearanceColposcopic Cervical BiopsyColposcopic DiagnosisHistologic ExaminationInvasive Cervical CarcinomaPostpartum Cervical Lesions
OBJECTIVE: To study the histologic regression and progression rates of cervical intraepithelial neoplasia (CIN) II and III after delivery and the effect the route of delivery has on the regression rates of CIN. METHODS: Pregnant patients with satisfactory colposcopic examinations and biopsy-proven CIN II and III were identified. Delivery information and postpartum biopsy results were obtained by chart review. RESULTS: Two hundred seventy-nine patients had antepartum biopsies of CIN II or CIN III. Of these, 126 women were excluded for the following reasons: lost to follow-up (75), human immunodeficiency virus positive (two), cesarean hysterectomy (four), and inadequate postpartum follow-up (45). This yielded a study group of 153 patients consisting of 82 with CIN II and 71 with CIN III. The regression rates were 68% and 70% among CIN II and CIN III patients (P = .78), respectively. Seven percent of patients with CIN II progressed to CIN III on postpartum evaluation. Twenty-five percent of those patients with CIN II and 30% of those with CIN III remained the same postpartum. No CIN lesions progressed to invasive carcinoma. There were no differences in regression rates or progression rates among the women who had vaginal deliveries (130), women who labored and then underwent cesarean (17), or women who proceeded to a cesarean without laboring (six). CONCLUSION: We found similar high postpartum regression rates despite the route of delivery. We recommend conservative antepartum management with postpartum colposcopic evaluation regardless of route of delivery because we are unable to predict which of these lesions are more likely to regress.
11
Interim Guidelines for Management of Abnormal Cervical Cytology
Robert J. Kurman · JAMA · 1994 · 542 citations
Medicine, Gynecology, Pathology +13
Risk factors for cervical cancer in Colombia and Spain
F. Xavier Bosch, Núbia Muñóz, Sílvia de Sanjosé et al. · International Journal of Cancer · 1992 · 309 citations
Medicine, Gynecology, Oncology +9